23:27 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Studies in mice suggest dual inhibition of IRS1 and IRS2 could help treat KRAS-mutant NSCLC. In a mouse model of KRAS-mutant NSCLC, lung-specific dual knockout of IRS1 and IRS2...
08:00 , Nov 13, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms CD8+ T cells that express phosphopeptide-targeted T cell receptor (TCR) to treat cancer Mouse studies suggest CD8+ T cells expressing TCRs that engage with phosphopeptide...
08:00 , Feb 18, 2013 |  BC Week In Review  |  Clinical News

MiReven, Silence Therapeutics preclinical data

In vitro, miR-7-5p significantly inhibited the migration and invasion of metastatic melanoma cells. The product is a miRNA targeting insulin receptor substrate 2 (IRS2) , an activator of protein kinase B (PKB; PKBA; AKT; AKT1)....